Selective agonist binding of (S)-2-amino-3-(3-hydroxy-5-methyl-4- isoxazolyl)propionic acid (AMPA) and 2S-(2α,3β,4β)-2-carboxy-4- (1-methylethenyl)-3-pyrrolidineacetic acid (kainate) receptors: A molecular modeling study

Biochemical Pharmacology

Volumn 66, Issue 12, 2003, Pages 2413-2425

  Pentikäinen, Olli T ^a   Settimo, Luca ^a   Keinänen, Kari ^b   Johnson, Mark S ^a  

^a ÅBO AKADEMI UNIVERSITY   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Agonist binding; Ionotropic glutamate receptors; Structural modeling; Structure activity relationship

Indexed keywords

4 METHYLGLUTAMIC ACID; 6,7 DINITRO 2,3 QUINOXALINEDIONE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ALPHA AMINO 5 TERT BUTYL 3 HYDROXY 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; AMPA RECEPTOR AGONIST; AMPA RECEPTOR ANTAGONIST; DOMOIC ACID; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR 1; GLUTAMATE RECEPTOR 2; GLUTAMATE RECEPTOR 3; GLUTAMATE RECEPTOR 4; GLUTAMATE RECEPTOR 5; GLUTAMATE RECEPTOR 6; GLUTAMATE RECEPTOR 7; GLUTAMIC ACID; GLUTARIC ACID DERIVATIVE; KAINIC ACID; KAINIC ACID RECEPTOR; KAINIC ACID RECEPTOR 1; KAINIC ACID RECEPTOR 2; KAINIC ACID RECEPTOR AGONIST; KAINIC ACID RECEPTOR ANTAGONIST; LIGAND; RO 48 8587; UNCLASSIFIED DRUG; WILLARDIINE;

AMINO ACID SEQUENCE; ARTICLE; CHEMICAL STRUCTURE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HYDROGEN BOND; MOLECULAR MODEL; NUCLEOTIDE BINDING SITE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MOTIF; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; X RAY ANALYSIS;

EID: 0344153957     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.08.013     Document Type: Article

References (70)

1. Brauner-Osborne H., Egebjerg J., Nielsen E.O., Madsen U., Krogsgaard-Larsen P. Ligands for glutamate receptors: design and therapeutic prospects. J. Med. Chem. 43:2000;2609-2645.
2. Lees G.J. Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders. Drugs. 59:2000;33-78.
3. Dingledine R., Borges K., Bowie D., Traynelis S.F. The glutamate receptor ion channels. Pharmacol. Rev. 51:1999;7-61.
4. Stensbol T.B., Madsen U., Krogsgaard-Larsen P. The AMPA receptor binding site: focus on agonists and competitive antagonists. Curr. Pharm. Des. 8:2002;857-872.
5. Conti P., De Amici M., De Micheli C. Selective agonists and antagonists for kainate receptors. Mini-Rev. Med. Chem. 2:2002;177-184.
6. Lampinen M., Pentikäinen O., Johnson M.S., Keinänen K. AMPA receptors and bacterial periplasmic amino acid-binding proteins share the ionic mechanism of ligand recognition. EMBO J. 17:1998;4704-4711.
7. Kawamoto S., Uchino S., Xin K.Q., Hattori S., Hamajima K., Fukushima J., Mishina M., Okuda K. Arginine-481 mutation abolishes ligand-binding of the AMPA-selective glutamate receptor channel alpha1-subunit. Brain Res. Mol. Brain Res. 47:1997;339-344.
8. Jouppila A., Pentikäinen O.T., Settimo L., Nyrönen T., Haapalahti J.P., Lampinen M., Mottershead D.G., Johnson M.S., Keinänen K. Determinants of antagonist binding at the alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid receptor subunit, GluR-D. Role of the conserved arginine 507 and glutamate 727 residues. Eur. J. Biochem. 269:2002;6261-6270.
9. Wo Z.G., Chohan K.K., Chen H., Sutcliffe M.J., Oswald R.E. Cysteine mutagenesis and homology modeling of the ligand-binding site of a kainate-binding protein. J. Biol. Chem. 274:1999;37210-37218.
10. Kizelsztein P., Eisenstein M., Strutz N., Hollmann M., Teichberg V.I. Mutant cycle analysis of the active and desensitized states of an AMPA receptor induced by willardiines. Biochemistry. 39:2000;12819-12827.
11. Banke T.G., Greenwood J.R., Christensen J.K., Liljefors T., Traynelis S.F., Schousboe A., Pickering D.S. Identification of amino acid residues in GluR1 responsible for ligand binding and desensitization. J. Neurosci. 21:2001;3052-3062.
12. Hogner A., Kastrup J.S., Jin R., Liljefors T., Mayer M.L., Egebjerg J., Larsen I.K., Gouaux E. Structural basis for AMPA receptor activation and ligand selectivity: crystal structures of five agonist complexes with the GluR2 ligand-binding core. J. Mol. Biol. 322:2002;93-109.
13. Paas Y., Devillers-Thiery A., Teichberg V.I., Changeux J.P., Eisenstein M. How well can molecular modelling predict the crystal structure: the case of the ligand-binding domain of glutamate receptors. Trends Pharmacol. Sci. 21:2000;87-92.
14. Swanson G.T., Green T., Sakai R., Contractor A., Che W., Kamiya H., Heinemann S.F. Differential activation of individual subunits in heteromeric kainate receptors. Neuron. 34:2002;589-598.
15. Lampinen M., Settimo L., Pentikäinen O.T., Jouppila A., Mottershead D.G., Johnson M.S., Keinänen K. Discrimination between agonists and antagonists by the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid-selective glutamate receptor. A mutation analysis of the ligand-binding domain of GluR-D subunit. J. Biol. Chem. 277:2002;41940-41947.
16. Nielsen M.M., Liljefors T., Krogsgaard-Larsen P., Egebjerg J. The selective activation of the glutamate receptor GluR5 by ATPA is controlled by serine 741. Mol. Pharmacol. 63:2003;19-25.
17. Fleck M.W., Cornell E., Mah S.J. Amino-acid residues involved in glutamate receptor 6 kainate receptor gating and desensitization. J. Neurosci. 23:2003;1219-1227.
18. Armstrong N., Mayer M., Gouaux E. Tuning activation of the AMPA-sensitive GluR2 ion channel by genetic adjustment of agonist-induced conformational changes. Proc. Natl. Acad. Sci. U.S.A. 100:2003;5736-5741.
19. Armstrong N., Sun Y., Chen G.Q., Gouaux E. Structure of a glutamate-receptor ligand-binding core in complex with kainate. Nature. 395:1998;913-917.
20. Armstrong N., Gouaux E. Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core. Neuron. 28:2000;165-181.
21. Sun Y., Olson R., Horning M., Armstrong N., Mayer M., Gouaux E. Mechanism of glutamate receptor desensitization. Nature. 417:2002;245-253.
22. Kasper C., Lunn M.L., Liljefors T., Gouaux E., Egebjerg J., Kastrup J.S. GluR2 ligand-binding core complexes: importance of the isoxazolol moiety and 5-substituent for the binding mode of AMPA-type agonists. FEBS Lett. 531:2002;173-178.
23. Jin R., Horning M., Mayer M.L., Gouaux E. Mechanism of activation and selectivity in a ligand-gated ion channel: structural and functional studies of GluR2 and quisqualate. Biochemistry. 41:2002;15635-15643.
24. Hogner A., Greenwood J.R., Liljefors T., Lunn M.L., Egebjerg J., Larsen I.K., Gouaux E., Kastrup J.S. Competitive antagonism of AMPA receptors by ligands of different classes: crystal structure of ATPO bound to the GluR2 ligand-binding core, in comparison with DNQX. J. Med. Chem. 46:2003;214-221.
25. Jin R., Gouaux E. Probing the function, conformational plasticity, and dimer-dimer contacts of the GluR2 ligand-binding core: studies of 5-substituted willardiines and GluR2 S1S2 in the crystal. Biochemistry. 42:2003;5201-5213.
26. Lunn M.L., Hogner A., Stensbol T.B., Gouaux E., Egebjerg J., Kastrup J.S. Three-dimensional structure of the ligand-binding core of GluR2 in complex with the agonist (S)-ATPA: implications for receptor subunit selectivity. J. Med. Chem. 46:2003;872-875.
27. Furukawa H., Gouaux E. Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core. EMBO J. 22:2003;2873-2885.
28. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. The protein data bank. Nucleic Acids Res. 28:2000;235-242.
29. Johnson M.S., Overington J.P. A structural basis for sequence comparisons: an evaluation of scoring methodologies. J. Mol. Biol. 233:1993;716-738.
30. Johnson M.S., May A.C.W., Rodionov M.A., Overington J.P. Discrimination of common protein folds: application of protein structure to sequence/structure comparisons. Methods Enzymol. 266:1996;575-598.
31. Lovell S.C., Word J.M., Richardson J.S., Richardson D.C. The penultimate rotamer library. Proteins. 40:2000;389-408.
32. Allen F.H., Kennard O. 3D Search and research using the Cambridge Structural Database. Chem. Des. Autom. News. 8:1993;31-37.
33. Matzen L., Engesgaard A., Ebert B., Didriksen M., Frolund B., Krogsgaard-Larsen P., Jaroszewski J.W. AMPA receptor agonists: synthesis protolytic properties and pharmacology of 3-isothiazolol bioisosteres of glutamic acid. J. Med. Chem. 40:1997;520-527.
34. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., Olson A.J. Automated docking using Lamarckian genetic algorithm and an empirical binding free energy function. J. Comp. Chem. 19:1998;1639-1662.
35. Cornell W.D., Cieplak P., Bayly C.I., Gould I.R., Merz K.M.J., Ferguson D.M., Spellmeyer D.C., Fox T., Caldwell J.W., Kollman P.A. A second generation force field for the simulation of proteins and nucleic acids. J. Am. Chem. Soc. 117:1995;5179-5197.
36. Weiner SJ, Kollman PA, Nguyen DT, Case DA. An all-atom force field for simulations of proteins and nucleic acids. J Comp Chem 1986;7:230-52.
37. Halgren T.A. Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions. J. Comp. Chem. 17:1996;520-552.
38. Goodford P.J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 28:1985;849-857.
39. Johansen T.N., Greenwood J.R., Frydenvang K., Madsen U., Krogsgaard-Larsen P. Stereostructure-activity studies on agonists at the AMPA and kainate subtypes of ionotropic glutamate receptors. Chirality. 15:2003;167-179.
40. Brehm L., Greenwood J.R., Hansen K.B., Nielsen B., Egebjerg J., Stensbol T.B., Brauner-Osborne H., Slok F.A., Kronborg T.T., Krogsgaard-Larsen P. (S)-2-Amino-3-(3-hydroxy-7,8-dihydro-6H-cyclohepta[d]isoxazol-4-yl)propionic acid, a potent and selective agonist at the GluR5 subtype of ionotropic glutamate receptors. Synthesis, modeling, and molecular pharmacology. J. Med. Chem. 46:2003;1350-1358.
41. Carcache L.M., Rodriguez J., Rein K.S. The structural basis for kainoid selectivity at AMPA receptors revealed by low-mode docking calculations. Bioorg. Med. Chem. 11:2003;551-559.
42. Mayer M.L., Olson R., Gouaux E. Mechanisms for ligand binding to GluR0 ion channels: crystal structures of the glutamate and serine complexes and a closed apo state. J. Mol. Biol. 311:2001;815-836.
43. Sack J.S., Saper M.A., Quiocho F.A. Periplasmic binding protein structure and function. Refined X-ray structures of the leucine/isoleucine/ valine-binding protein and its complex with leucine. J. Mol. Biol. 206:1989;171-191.
44. Oh B.H., Pandit J., Kang C.H., Nikaido K., Gokcen S., Ames G.F., Kim S.H. Three-dimensional structures of the periplasmic lysine/arginine/ornithine- binding protein with and without a ligand. J. Biol. Chem. 268:1993;11348-11355.
45. Yao N., Trakhanov S., Quiocho F.A. Refined 1.89 Å structure of the histidine-binding protein complexed with histidine and its relationship with many other active transport/chemosensory proteins. Biochemistry. 33:1994;4769-4779.
46. Hsiao C.D., Sun Y.J., Rose J., Wang B.C. The crystal structure of glutamine-binding protein from Escherichia coli. J. Mol. Biol. 262:1996;225-242.
47. Fletcher E.J., Lodge D. New developments in the molecular pharmacology of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate and kainate receptors. Pharmacol. Ther. 70:1996;65-89.
48. Jane D.E., Hoo K., Kamboj R., Deverill M., Bleakman D., Mandelzys A. Synthesis of willardiine and 6-azawillardiine analogs: pharmacological characterization on cloned homomeric human AMPA and kainate receptor subtypes. J. Med. Chem. 40:1997;3645-3650.
49. Bjerrum E.J., Kristensen A.S., Pickering D.S., Greenwood J.R., Nielsen B., Liljefors T., Schousboe A., Brauner-Osborne H., Madsen U. Design, synthesis, and pharmacology of a highly subtype-selective GluR1/2 agonist, (R,S)-2-amino-3-(4-chloro-3-hydroxy-5-isoxazolyl)propionic acid (Cl-HIBO). J. Med. Chem. 46:2003;2246-2249.
50. Zhou L.M., Gu Z.Q., Costa A.M., Yamada K.A., Mansson P.E., Giordano T., Skolnick P., Jones K.A. (2S,4R)-4-methylglutamic acid (SYM 2081): a selective, high-affinity ligand for kainate receptors. J. Pharmacol. Exp. Ther. 280:1997;422-427.
51. Sakai R., Swanson G.T., Shimamoto K., Green T., Contractor A., Ghetti A., Tamura-Horikawa Y., Oiwa C., Kamiya H. Pharmacological properties of the potent epileptogenic amino acid dysiherbaine, a novel glutamate receptor agonist isolated from the marine sponge Dysidea herbacea. J. Pharmacol. Exp. Ther. 296:2001;650-658.
52. Donevan S.D., Beg A., Gunther J.M., Twyman R.E. The methylglutamate, SYM 2081, is a potent and highly selective agonist at kainate receptors. J. Pharmacol. Exp. Ther. 285:1998;539-545.
53. Pedregal C., Collado I., Escribano A., Ezquerra J., Dominguez C., Mateo A.I., Rubio A., Baker S.R., Goldsworthy J., Kamboj R.K., Ballyk B.A., Hoo K., Bleakman D. 4-Alkyl- and 4-cinnamylglutamic acid analogues are potent GluR5 kainate receptor agonists. J. Med. Chem. 43:2000;1958-1968.
54. Swanson G.T., Gereau R.W., Green T., Heinemann S.F. Identification of amino acid residues that control functional behavior in GluR5 and GluR6 kainate receptors. Neuron. 19:1997;913-926.
55. Swanson G.T., Green T., Heinemann S.F. Kainate receptors exhibit differential sensitivities to (S)-5-iodowillardiine. Mol. Pharmacol. 53:1998;942-949.
56. Keinänen K., Jouppila A., Kuusinen A. Characterization of the kainate-binding domain of the glutamate receptor GluR-6 subunit. Biochem. J. 330:1998;1461-1467.
57. Willis C.L., Wacker D.A., Bartlett R.D., Bleakman D., Lodge D., Chamberlin A.R., Bridges R.J. Irreversible inhibition of high-affinity [3H]kainate binding by a novel photoactivatable analogue: (2′S,3′S, 4′R)-2′-carboxy-4′-(2-diazo-1-oxo-3,3,3-trifluoropropyl) -3′-pyrrolidinyl acetate. J. Neurochem. 68:1997;1503-1510.
58. Nielsen P.A., Liljefors T. Conformational analysis of kainate in aqueous solution in relation to its binding to AMPA and kainic acid receptors. J. Comp. Aided Mol. Des. 15:2001;753-763.
59. Kwak S., Aizawa H., Ishida M., Shinozaki H. New, potent kainate derivatives: comparison of their affinity for [3H]kainate and [3H]AMPA binding sites. Neurosci. Lett. 139:1992;114-117.
60. Cantrell B.E., Zimmerman D.M., Monn J.A., Kamboj R.K., Hoo K.H., Tizzano J.P., Pullar I.A., Farrell L.N., Bleakman D. Synthesis of a series of aryl kainic acid analogs and evaluation in cells stably expressing the kainate receptor humGluR6. J. Med. Chem. 39:1996;3617-3624.
61. Sonnenberg J.D., Koch H.P., Willis C.L., Bradbury F., Dauenhauer D., Bridges R.J., Chamberlin A.R. The role of the C-4 side chain of kainate and dihydrokainate in EAA receptor and transporter selectivity. Bioorg. Med. Chem. Lett. 6:1996;1607-1612.
62. Hashimoto K., Matsumoto T., Nakamura K., Ohwada S., Ohuchi T., Horikawa M., Konno K., Shirahama H. Molecular orbital calculation for the model compounds of kainoid amino acids, agonists of excitatory amino acid receptors. Does the kainoid C4-substituent directly interact with the receptors? Bioorg. Med. Chem. 10:2002;1373-1379.
63. Kraulis P.J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24:1991;946-950.
64. Merritt E.A., Bacon D.J. Raster3D: photorealistic molecular graphics. Methods Enzymol. 277:1997;505-524.
65. Sommer B., Keinänen K., Verdoorn T.A., Wisden W., Burnashev N., Herb A., Kohler M., Takagi T., Sakmann B., Seeburg P.H. Flip and flop: a cell-specific functional switch in glutamate-operated channels of the CNS. Science. 249:1990;1580-1585.
66. Barton G.J. ALSCRIPT: a tool to format multiple sequence alignments. Protein Eng. 6:1993;37-40.
67. Small B., Thomas J., Kemp M., Hoo K., Ballyk B., Deverill M., Ogden A.M., Rubio A., Pedregal C., Bleakman D. LY339434, a GluR5 kainate receptor agonist. Neuropharmacology. 37:1998;1261-1267.
68. Clarke V.R., Ballyk B.A., Hoo K.H., Mandelzys A., Pellizzari A., Bath C.P., Thomas J., Sharpe E.F., Davies C.H., Ornstein P.L., Schoepp D.D., Kamboj R.K., Collingridge G.L., Lodge D., Bleakman D. A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission. Nature. 389:1997;599-603.
69. Coquelle T., Christensen J.K., Banke T.G., Madsen U., Schousboe A., Pickering D.S. Agonist discrimination between AMPA receptor subtypes. Neuroreport. 11:2000;2643-2648.
70. Stensbol T.B., Slok F.A., Trometer J., Hurt S., Ebert B., Kjoller C., Egebjerg J., Madsen U., Diemer N.H., Krogsgaard-Larsen P. Characterization of a new AMPA receptor radioligand, [3H]2-amino-3-(3-carboxy-5-methyl-4-isoxazolyl) propionic acid. Eur. J. Pharmacol. 373:1999;251-262.